1. Home
  2. BIOA
  3. BIOA News

Latest BioAge Labs Inc. Common Stock (BIOA) News on December 18, 2024

BIOA

MT Newswires

7 hours ago

BioAge Labs Says it is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
BIOA

GlobeNewswire

8 hours ago

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

3 closely watched drugs that failed in the clinic
BIOA

Pharma Voice

3 days ago

3 closely watched drugs that failed in the clinic

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
BIOA

Clinical Trials Arena

9 days ago

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

BIOA

MT Newswires

9 days ago

Top Premarket Decliners

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
BIOA

Benzinga

9 days ago

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

BIOA

MT Newswires

9 days ago

Jefferies Downgrades BioAge Labs to Hold From Buy, Adjusts Price Target to $7 From $42

BIOA

MT Newswires

9 days ago

Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45

BioAge shares tumble after decision to halt obesity drug study
BIOA

BioPharma Dive

11 days ago

BioAge shares tumble after decision to halt obesity drug study

BIOA

MT Newswires

12 days ago

BioAge Labs Terminates Phase 2 Trial of Obesity Drug Candidate

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
BIOA

GlobeNewswire

12 days ago

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
BIOA

GlobeNewswire

13 days ago

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?
BIOA

Insider Monkey

14 days ago

Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?

BioAge Labs to Present at Upcoming Investor Conferences
BIOA

GlobeNewswire

a month ago

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports Strong Q3 2024 Achievements
BIOA

TipRanks

a month ago

BioAge Labs Reports Strong Q3 2024 Achievements

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
BIOA

GlobeNewswire

a month ago

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
BIOA

GlobeNewswire

a month ago

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BioAge Labs to Present at Jefferies London Healthcare Conference
BIOA

GlobeNewswire

2 months ago

BioAge Labs to Present at Jefferies London Healthcare Conference

BIOA

Investing.com

2 months ago

Wall Street analysts initiate coverage of BioAge Labs

Prediction: These 2 Stocks Could Soar in 2025
BIOA

Motley Fool

2 months ago

Prediction: These 2 Stocks Could Soar in 2025

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
BIOA

Motley Fool

2 months ago

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc
BIOA

GuruFocus.com

2 months ago

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
BIOA

Motley Fool

2 months ago

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

This IPO Biotech Stock Could Be the Next Eli Lilly
BIOA

Motley Fool

3 months ago

This IPO Biotech Stock Could Be the Next Eli Lilly

BIOA

MT Newswires

3 months ago

BioAge Labs Raises $238.3 Million From IPO, Private Placement

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
BIOA

GlobeNewswire

3 months ago

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

Share on Social Networks: